{"entity":{"id":"nct07146672","kind":"trial","name":"Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors","aka":[],"tldr":"A phase 1/2 trial of Super DC Vaccine in advanced solid tumours, run by Shanghai Cell Therapy Group Co.,Ltd, now recruiting.","summary":"Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors is a phase 1/2 interventional study registered as NCT07146672 by Shanghai Cell Therapy Group Co.,Ltd, with 12 participants planned, started 2025-07-31 and due to reach its primary completion in 2026-12-31. Interventions recorded: Super DC Vaccine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07146672","url":"https://clinicaltrials.gov/study/NCT07146672"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["dendritic-cell-vaccines"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07146672","phase":"1/2","setting":"Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors","sponsor":"Shanghai Cell Therapy Group Co.,Ltd","started":"2025-07-31","startedType":"actual","enrolled":12,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07146672/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"dendritic-cell-vaccines","kind":"technology","name":"Dendritic cell vaccines","route":"/technologies/dendritic-cell-vaccines/"}]}}